Lincoln Pharma Q1 FY27 net profit up 31% YoY to Rs 36.23 cr

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹591.50

prior close

₹608.30

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+4.9% vs market

Pharmaceuticals peers, median of 166sector+0.1%+4.9% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.6

10m

+2.3

15m

+2.3

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.2+4.9+0.1+4.9

Next day

+3.5+0.2+3.3-0.3+3.8

+5.5+0.4+5.1-0.2+5.7

+4.4+0.7+3.7-0.4+4.8

+4.5+0.1+4.3-1.5+5.9

+5.1+0.7+4.4-0.9+6.0

+3.4+1.2+2.3-0.6+4.1

15d

+5.6+0.7+4.8+0.3+5.3

+1.4-1.2+2.6-0.2+1.6

-6.9-1.1-5.8-2.3-4.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharma Q1 FY27 (quarter ended June 2026) reported total income of Rs 201.55 crore, up 19% YoY. Net profit rose 30.9% to Rs 36.23 crore from Rs 27.68 crore. EBITDA grew 32.3% to Rs 51.70 crore. EPS stood at Rs 18.09 versus Rs 13.82 last year. The company targets Rs 1,000 crore revenue over 3 years, remains net-debt free, and recommended an 18% dividend for FY26.

Likely market impact

Strong profit and EBITDA growth signals healthy momentum. Net-debt-free balance sheet, CRISIL A rating, and 18% dividend add to shareholder appeal.